10 pharmaceutical forecasting experts
Pharmaceutical forecasting titles in this group are split mostly by therapy area or deal stage: rare disease, cardiovascular, oncology and general medicines forecasting sit beside a BD&L forecasting director at CSL and Head of Global Forecasting titles at Genmab and CSL. Two hold Executive Director forecasting titles, at Amgen and Merck, and the group suits a drug company building a launch or pipeline forecast or deciding how much weight leadership should give it.
Professionals to explore
Andre Sanchez
LinkedInExperience: Director - Commercial Forecasting in Cardiovascular · Amgen
$438 per 30-minute call
Andre Sanchez's Amgen forecasting titles move across therapy areas: Director - Commercial Forecasting in Cardiovascular (since 2025), Associate Director - Commercial Forecasting & Analytics in Obesity (2024–2025), Senior Manager - Global Commercial Forecasting in Rare Disease (2023–2024), Senior Manager - Commercial Forecasting in Inflammation (2021–2023) and Manager - Commercial Forecasting in Oncology (2019–2021). Andre leads the commercial forecasting team for the cardiovascular business unit.
Is this you? Claim your profile and get paid for calls.
Ben Zimmerman
LinkedInExperience: Head of Global Forecasting and Business Analytics · Genmab
$673 per 30-minute call
Genmab's Head of Global Forecasting and Business Analytics since 2024, Ben Zimmerman covers global forecasting and analytics across the portfolio in oncology, hematology, immunology and inflammation. At Bristol Myers Squibb, Ben was International Market Insights & Capabilities Senior Director (2021–2024), Oncology Strategic Planning & Forecasting Director (2020–2021) and Oncology Strategic Planning & Forecasting Associate Director (2016–2020).
Is this you? Claim your profile and get paid for calls.
Brian Binns
LinkedInExperience: Former Director, US Forecasting - Rare Disease · AstraZeneca
$438 per 30-minute call
Rare disease runs through Brian Binns's titles: Director, US Forecasting - Rare Disease at AstraZeneca (2024–2026), Director, Forecasting and Business Analytics - Rare Disease at Mirum Pharmaceuticals, Inc. (2022–2023) and Sr. Manager - Forecasting & Analytics - Rare Disease at BioMarin Pharmaceutical Inc. (2020–2022). Since 2026, Brian has been Director, US Forecasting - HIV PrEP at Gilead Sciences, and the rare disease years make Brian a fit for rare disease launch forecasts.
Is this you? Claim your profile and get paid for calls.
Cyril Thomson
LinkedInExperience: Sr. Director and Head of Global Commercial Forecasting and Portfolio Analytics · CSL
$539 per 30-minute call
Long-range forecasting and decision analytics for a ~$13B+ portfolio of 30+ assets across multiple therapy areas are part of Cyril Thomson's own description. At CSL, Cyril has been Sr. Director and Head of Global Commercial Forecasting and Portfolio Analytics (since 2024), following Director, Global Commercial Forecasting and Decision Analytics (2020–2024) and Global Commercial Forecasting Lead (2019–2020), and was earlier Principal at IQVIA (2017–2019).
Is this you? Claim your profile and get paid for calls.
Jeffrey Seguritan
LinkedInExperience: Director, US General Medicines Forecasting · Sanofi
$438 per 30-minute call
From 2019 to 2023, Jeffrey Seguritan was Director, US General Medicines Forecasting at Sanofi, leading forecast planning and development of a US General Medicines portfolio (Diabetes, Cardiovascular, Transplant, Endo-Oncology, Legacy & Generics) covering 100+ SKUs and managing a team of forecasting professionals. Jeffrey has been Director, CardioMetabolic Strategic Analytics at Sanofi since 2023 and was Director, General Medicines Forecasting there (2018–2019).
Is this you? Claim your profile and get paid for calls.
Jonas Sibomana
LinkedInExperience: Senior Director, Forecasting and Performance Reporting · Sage Therapeutics
$336 per 30-minute call
Jonas Sibomana has been Senior Director, Forecasting and Performance Reporting at Sage Therapeutics since 2022, after Director, Global Respiratory Biologics Insights & Analytics at AstraZeneca (2021–2022). Earlier AstraZeneca titles include Forecasting Director, US Respiratory Biologics (2019–2021) and Insights Forecasting Leader Respiratory inhaled (2016–2019), a fit for questions on tying forecasts to performance reporting.
Is this you? Claim your profile and get paid for calls.
Michael Bragin
LinkedInExperience: Director BD&L Forecasting and Analytics · CSL
$404 per 30-minute call
At CSL since 2025, Michael Bragin has been Director BD&L Forecasting and Analytics, supporting commercial assessment and BD&L due diligence through commercial revenue forecasting and product and pipeline portfolio analytics. Michael was Director, North American Forecasting & Analytics at Kyowa Kirin, Inc.- U.S. (2023–2024), Director, Forecasting & Commercial Analytics at Karyopharm Therapeutics Inc. (2022–2023) and Sr. Manager, Global Oncology Forecasting & Strategic Analytics at GSK (2019–2022).
Is this you? Claim your profile and get paid for calls.
Nicole Anderson
LinkedInExperience: Executive Director, US Forecasting · Amgen
$539 per 30-minute call
Executive Director, US Forecasting at Amgen since 2026, Nicole Anderson was Director Rare Disease Forecasting there (2024–2026) and held Business Development Forecasting & Analytics at Amgen (2022–2024). Nicole was Sr. Mgr Pipeline & BD Forecasting at Lundbeck (2021–2022) and Controller, Global Operations at Johnson Controls (2019–2020), a finance background useful when reconciling a forecast with finance.
Is this you? Claim your profile and get paid for calls.
Parth Parikh
LinkedInExperience: Director, Forecasting · Teva Pharmaceuticals
$370 per 30-minute call
Teva Pharmaceuticals (Innovative Medicines) has had Parth Parikh as Director, Forecasting since 2024, after Director, Global Forecasting at BioCryst Pharmaceuticals, Inc. (2023–2024). Parth was also Director, Forecasting (Malignant & Non-malignant Hematology) at Novartis (2021–2023), Associate Director, Insights & Analytics (Sandoz Inc, A Novartis company) (2019–2021) and Associate Director, Forecasting at Helsinn Group (2018–2019).
Is this you? Claim your profile and get paid for calls.
Puneet Swami
LinkedInExperience: Former Head of Oncology Forecasting & Insights- US and Global · Merck
$673 per 30-minute call
Puneet Swami was Head of Oncology Forecasting & Insights- US and Global at Merck (2023–2025) and has been Executive Director Strategic Forecasting Merck since 2026, covering enterprise-wide strategic forecasting. Puneet also held Head of Solid Tumors Forecasting US & Global (2023) and Director Global Oncology Forecasting & Analytics (2021–2023) at Takeda Oncology, and US Oncology Enterprise Strategy & Analytics at Bristol Myers Squibb (2020–2021).
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
For pipeline assets under deal review, Michael Bragin and Nicole Anderson have held business development forecasting titles; for portfolio-wide views, Cyril Thomson, Ben Zimmerman and Puneet Swami hold global or enterprise forecasting roles. Otherwise pick by therapy area: Brian Binns for rare disease, Andre Sanchez for cardiovascular and obesity, Parth Parikh for hematology, Jeffrey Seguritan for general medicines and Jonas Sibomana for respiratory and performance reporting.
Questions to take into the conversation
- 01How do you build a forecast for a drug that has not launched yet, and which assumptions move the number most?
- 02How do you reconcile a forecast with what commercial and finance leaders want to see, and how do you handle pushback?
- 03What do you track after launch to tell whether the forecast was wrong or the execution was?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.